-
UPDATE: Burrill Institutional Research Downgrades Sarepta Therapeutics on Valuation
Wednesday, July 24, 2013 - 10:42am | 171In a report published Wednesday, Burrill Institutional Research analyst Reni Benjamin downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Market Outperform to Market Perform, and removed the $39.00 price target. In the report, Burrill Institutional Research noted, “We are downgrading our rating...